Abstract. In the present study, the case of a 41-year-old man with immunoglobulin (Ig)M multiple myeloma (MM) that presented with an unusually non-aggressive clinical course who has survived for >9 years to date, is presented. Initial diagnosis of symptomatic MM was established according to the International Myeloma Working Group consensus statement and guidelines. Due to the mild symptoms, no therapy was administered and the patient was closely followed up. Eight years after initial diagnosis, clinical, morphological and genetic progression occurred with the development of hypercalcemia, progressively deteriorating polyneuropathy, clonal expansion of plasma cells up to 50% of hematopoietic cells and demonstration of the typical t(11;14) translocation (Ig heavy chain locus rearrangement). Subsequently, 4 cycles of induction chemotherapy with velcade, cyclophosphamide and dexamethasone, were administered. At the time of writing, the patient remained alive in generally good health. To the best of our knowledge, with a survival time of >9 years, this case reports the longest survival time of an IgM MM patient to date, which contradicts previous evidence that suggests IgM MM exhibits an aggressive clinical course.
Introduction
Multiple myeloma (MM) accounts for 10% of all hematological malignancies and is a B-cell malignancy characterized by a clonal proliferation of abnormal plasma cells in the bone marrow (1, 2) . MM occurs most frequently in patients between the ages of 50 and 80 years (3) . MM is characterized by the presence of monoclonal immunoglobulin (Ig) in the serum, of which IgG and IgA are the most frequently observed subtypes (4) . IgM MM is an extremely rare lymphoproliferative disease associated with an aggressive clinical course, which accounts for <0.5% of all MM cases (4, 5) . Distinguishing IgM MM from Waldenström's macroglobulinemia (WM) is extremely important, but is often challenging due to similar characteristics (6) . Differentiation may be established based on clinical presentation or bone marrow morphology (7) . Diagnosis of IgM MM is usually established based on the International Myeloma Working Group criteria, which state that IgM MM includes: i) The presence of M-protein in the serum and/or urine; ii) >10% bone marrow clonal plasma cells or plasmacytoma; and iii) associated organ or tissue impairment (end organ damage, including bone lesions) (8) . The median reported survival for IgM MM is 36 months (9) . In this study, the case of a 41-year-old man who presented with immunoglobulin (Ig)M multiple myeloma (MM) with an unusually non-aggressive clinical course is presented. A watch-and-wait strategy was adopted, however clinical progression occurred after eight years. At present the patient remains alive nine years after the initial diagnosis. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Case report
In October 2005, a 41-year-old man with an unremarkable medical history presented to the Coffs Harbour Health Campus, Coffs Harbour, Australia, with the complaint of tingling and burning paresthesia in both feet and exertional dyspnea. No hepatosplenomegaly or lymphadenopathy was identified and physical examination was otherwise unremarkable. The laboratory examination results at initial presentation were as follows: White blood cell count, 6.2x10 9 /l (reference range, 4.0-12.0x10 9 /l); hemoglobin, 150 g/l (reference range, 130-180 g/l); platelet count, 281x10 9 /l (reference range, 150-400x10 9 /l); erythrocyte sedimentation rate, 115 mm/h (reference range, 1-10 mm/h); creatinine, 0.10 mmol/l (reference range, 0.05-0.12 mmol/l), blood urea nitrogen, 6.7 mmol/l (reference range, 2.5-6.5 mmol/l); calcium, 2.61 mmol/l (reference range, 2. 
Discussion
Distinguishing IgM MM from WM is critical; however, it may be difficult. IgM MM and WM are two distinct hematological entities with the common symptom of an IgM monoclonal gammopathy (6) . Differentiation may be established based on clinical presentation or BM morphology. The clinical symptoms of anemia, hypercalcemia, renal impairment, lytic bone lesions, and plasma cell infiltration of BM clearly indicate the rare diagnosis of IgM MM (7). However, the above-mentioned criteria are not highly sensitive. Lymphadenopathy and hepatosplenomegaly, two symptoms of WM, are typically present in only 20-40% of all WM cases (6) . Furthermore, bone lesions are not always present in IgM MM (10) . Recently, the presence of t (11;14) in IgG MM has been demonstrated to be highly specific (11) . Translocation t (11;14) leads to dysregulation of cyclin D1 and has been identified in 7/8 patients with IgM myeloma in a study by Avet-Loiseau et al (11) , while no such translocation was identified in all 17 cases of WM. In addition, recently a mutation in exon 5 of the MYD88 gene (MYD88 L265P), which is absent in IgM MM patients, was demonstrated to be specific for WM with a specificity of >90% (12) . Due to the extremely rare incidence of IgM MM, only a few case series have been reported in the literature to date (4, 5, 9) . Notably, IgM MM appears to be more aggressive than IgG or IgA MM, as well as WM, with an overall median survival time of 36 months (9) . In addition, IgM MM has a poor clinical outcome in the context of high-dose therapy (13) . To date, the longest reported survival time of a patient with IgM myeloma was 60 months (5) . At present, treatment guidelines recommend the same therapeutic approach for IgM MM and IgG or IgA myelomas (14) . Notably, IgM monoclonal gammopathy of unknown significance has a benign course with no progression to IgM MM (15) .
In the present case, the clinical presentation was atypical; the patient initially presented with polyneuropathy, without hypercalcemia, anemia, renal impairment or lytic bone lesions. However, diagnosis of symptomatic MM was established according to the International Myeloma Working Group consensus statement and guidelines (8) . Due to the mild symptoms observed, no therapy was initiated and the patient was closely followed up. However, 8 years after initial diagnosis clinical, morphological and genetic progression occurred, with the development of hypercalcemia, progressively deteriorating polyneuropathy, clonal expansion of plasma cells up to 50 of hematopoietic cells and demonstration of the typical t(11;14) translocation (IGH locus rearrangement). In conclusion, to the best of our knowledge, the survival time of the symptomatic IgM MM patient in this case is the longest to be reported in the literature to date, which contradicts previous evidence that suggests IgM MM exhibits an aggressive clinical course (9) .
IgM MM may have a more heterogeneous disease course than was previously understood. However, larger observational studies are required in order to identify the potential risk and protecting factors that result in an aggressive or comparatively non-aggressive IgM MM course, respectively.
